Monday - March 23, 2026

Category Archives: Business

Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight

Hypersomnia Pipeline Key Hypersomnia companies involved in drug development include Axsome Therapeutics, Alkermes, Zevra Therapeutics, Takeda, and Aexon Labs, among others. Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight Key Hypersomnia companies involved … Continue reading →

ALK-Positive NSCLC Pipeline Gains Momentum as 6+ Pharma Companies Advance Next-Generation Therapies | DelveInsight

ALK-Positive NSCLC Pipeline ALK-positive Non-Small Cell Lung Cancer Companies include Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others. The treatment landscape for ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) is rapidly evolving, driven by continuous research and innovation from … Continue reading →

Restrictive Cardiomyopathy Market Set for Notable Growth Through 2034, Driven by Advancing Therapies and Rising Disease Awareness | DelveInsight

Restrictive Cardiomyopathy Market Restrictive Cardiomyopathy companies include Array Biopharma, AstraZeneca, Sanofi, Hoffmann-La Roche, Merck & Co., Pfizer, Capricor Therapeutics, MyoKardia, Janssen, GSK, Teva Pharmaceuticals, Cipla, and Sun Pharmaceuticals, among others. DelveInsight’s latest report, “Restrictive Cardiomyopathy Market Insights, Epidemiology, and Market … Continue reading →

Diarrhea Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Diarrhea Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Diarrhea pipeline landscape. It covers the Diarrhea Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diarrhea Pipeline … Continue reading →

Diabetes Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveInsight

DelveInsight’s “Diabetes Pipeline Insight 2026” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes therapeutics … Continue reading →

Genital Herpes Clinical Trial Pipeline Shows Potential with Active Contributions from 18+ Key Companies | DelveInsight

DelveInsight’s, “Genital Warts Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Shows Potential with Active Contributions from 70+ Key Companies | DelveInsight

DelveInsight’s, “Antisense Oligonucleotide Therapeutics Pipeline Insights 2026” report provides comprehensive insights about 70+ companies and 90+ pipeline drugs in the Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the Antisense Oligonucleotide Therapeutics pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

c-MET-NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the C-MET+ NSCLC pipeline drug profiles, including … Continue reading →

PD-1+ NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical … Continue reading →